ArticleRadiation oncology (London, England)2021
Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024.European radiology · 2026Article
- Clinical outcomes after interstitial high-dose-rate brachytherapy vs. stereotactic body radiotherapy in hepatocellular carcinoma: A retrospective matched single-center analysis.Journal of contemporary brachytherapy · 2026Article
- Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy andClinical and translational radiation oncology · 2026Article
- Article
- Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors.Physics and imaging in radiation oncology · 2025Article
- Efficacy and factors related to prognosis of combination chemotherapy with different radiotherapy methods in patients with unresectable hepatocellular carcinoma.Scientific reports · 2025Article
- Diaphragm and lung dose in liver high-dose-rate interstitial brachytherapy: A dosimetry and toxicity report.Journal of contemporary brachytherapy · 2025Article
- The role of brachytherapy in liver metastases from colorectal cancer.Frontiers in immunology · 2025Article
- Multi-scale channel attention U-Net: a novel framework for automated gallbladder segmentation in medical imaging.Frontiers in oncology · 2025Article
- Interstitial High-Dose-Rate Brachytherapy Combined with External Beam Radiation Therapy for Dose Escalation in the Primary Treatment of Locally Advanced, Non-Resectable Superior Sulcus (Pancoast) Tumors: Results of a Monocentric Retrospective Study.Journal of clinical medicine · 2024Article
- HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases - A dosimetric comparison study of three radioablative techniques.Clinical and translational radiation oncology · 2024Article
- Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs.Frontiers in oncology · 2024Article
- Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites.Journal of contemporary brachytherapy · 2022Article
- The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Review
- Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients.Cancers · 2021Article
- Dosimetric Comparison of Intraoperative Radiotherapy and SRS for Liver Metastases.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn unresectable hepatocellular carcinoma several local ablative treatments are available. Among others, radiation based treatments such as stereotactic body radiotherapy (SBRT) and high-dose rate interstitial brachytherapy (HDR BT) have shown good local control rates.
methodsWe conducted a dose comparison between actually performed HDR BT versus virtually planned SBRT to evaluate the respective clinically relevant radiation exposure to uninvolved liver tissue. Moreover, dose coverage and conformity indices were assessed.
resultsOverall, 46 treatment sessions (71 lesions, 38 patients) were evaluated. HDR BT was applied in a single fraction with a dose prescription of 1 × 15 Gy. D98 was 17.9 ± 1.3 Gy, D50 was 41.8 ± 8.1 Gy. The SBRT was planned with a prescribed dose of 3 × 12.5 Gy (65%-Isodose), D98 was 50.7 ± 3.1 Gy, D2 was 57.0 ± 2.3 Gy, and D50 was 55.2 ± 2.3 Gy. Regarding liver exposure Vliver10Gy
conclusionHDR BT can be advantageous in respect of sparing of normal liver tissue as compared to SBRT, while providing excellent target conformity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.